Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orlistat for Uric Acid Reduction in Overweight/Obese Patients
NCT05496075Phase 4Completed
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of orlistat in hyperuricemia (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoint: level of uric acid at Month 3. Started Aug 2022; status: completed.
02
Drugs
orlistat
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on NCT05496075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05496075.